AllAnalyst Report
logoMorningstarOctober 19, 2020

Myriad Genetics, Inc.: Taking a Fresh Look at Myriad Genetics; Downgrading Moat to None From Narrow and Reducing FVE to $11

Symbols
MYGN
Sector(s)
Healthcare
Rating
Premium
Current Price
$18.88
Fair Value
Premium
Economic Moat
Premium
Stewardship
Premium
Summary

Myriad Genetics is a molecular diagnostics company, which provides testing services designed to assess an individual’s risk of developing a disease. The firm produces myRisk, a 35-gene panel with the capability to identify the elevated risk of developing 8 types of cancer. Other diagnostic products include BRACAnalysisCDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; Vectra DA, which predicts disease progression in rheumatoid arthritis to optimize drug treatment; and Prolaris, which identifies prostate cancer patients that can pursue active surveillance. The firm also offers biomarker discovery and companion diagnostic services to pharmaceutical and biotechnology companies.

Premium
Subscribe to Yahoo Finance Premium for full access
Read the latest independent research including analyst forecasts, ratings on the US economy, and more. Get individual company and overall sector level recommendations.
Try Premium FREE